What is PLX's Value Score?

Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) has a StockPik Value Score of 89 out of 100 — a high score, indicating strong value characteristics across multiple metrics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is PLX's Piotroski F-Score?

Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) has a Piotroski F-Score of 4 out of 9 — a moderate score. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

Is PLX trading below its Graham Number?

PLX is currently trading above its Graham Number. The stock price of $2.1 exceeds the Graham Number of $2, meaning it does not meet Graham's criterion for a margin of safety at the current price. The Graham Number is calculated as √(22.5 × EPS × Book Value Per Share) and represents Benjamin Graham's ceiling price for a defensive investor.

What is PLX's Graham Number?

PLX's Graham Number is $2.00, calculated using the Benjamin Graham formula √(22.5 × EPS × Book Value per Share). The Graham Number is an estimate of intrinsic value — the maximum price a defensive investor should pay. At the current price of $2.10, PLX is trading 5% above its Graham Number.

What is PLX's Piotroski F-Score?

PLX's Piotroski F-Score is 4 out of 9, indicating moderate financial health. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is PLX (Protalix BioTherapeutics, Inc. (DE) Common Stock) undervalued?

PLX scores 89/100 on StockPik's Value Score, placing it in undervalued territory. The stock trades 5% above its Graham Number of $2.00.

What is PLX's P/E ratio?

PLX's trailing P/E ratio is 9.8x — a low earnings multiple, suggesting the stock may be undervalued relative to its earnings. The Healthcare sector average P/E is 25.2x. Compare against other Healthcare stocks in the StockPik screener.

What sector is Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) in?

Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) is in the Healthcare sector, specifically in the Biological Products, (No Diagnostic Substances) industry. Compare it against other Healthcare stocks by Value Score, P/E ratio, and Piotroski F-Score on StockPik.

Back to Screener

Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)

AMEX Micro Cap

Healthcare › Biological Products, (No Diagnostic Substances)

$2.10

Market Cap: $169M

Data as of Mar 31, 2026 (TTM)

Price History

Feb 9, 2026 — May 24, 2026

Investment Snapshot

Trading 5% above Graham Number — above intrinsic value estimate
Piotroski F-Score 4/9 — moderate financial health
Strong ROE of 25.6% with 22.3% net margin

Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the AMEX , with a market capitalisation of $169 million . Key value metrics: P/E ratio 9.8, P/B ratio 2.52, Piotroski F-Score 4 out of 9 (moderate financial health) .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

9.83

P/B Ratio

2.52

EPS

$0.21

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Current vs 5-Year Average

Based on 5 years of SEC filings

Net Margin

—

↑ +2.1pp avg —

Gross Margin

—

↑ +2.1pp avg —

Operating Margin

—

↑ +2.1pp avg —

Return on Equity

—

↑ +2.1pp avg —

Debt / Equity

—

↑ +2.1pp avg —

See How Margins & ROE Have Trended — Try PRO

Revenue & Net Income

Profit Margins

Track Gross, Operating & Net Margins — Try PRO

EPS & Free Cash Flow Per Share

See EPS & Free Cash Flow Trends — Try PRO

Financial Statements

Metric	FY22	FY23	FY24
Revenue	$X.XB	$X.XB	$X.XB
Gross Profit	$X.XB	$X.XB	$X.XB
Operating Income	$X.XB	$X.XB	$X.XB
Net Income	$X.XB	$X.XB	$X.XB
EBITDA	$X.XB	$X.XB	$X.XB
Total Assets	$X.XB	$X.XB	$X.XB
Total Liabilities	$X.XB	$X.XB	$X.XB

Unlock 5 Years of Financials — Start Free Trial

Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

Protalix BioTherapeutics, Inc. (DE) Common Stock — Fundamental Analysis Summary

Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) is currently trading 5% above its Graham Number of $2.00, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 9.8x.

On financial health, PLX shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 25.6% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.55.

StockPik's composite Value Score for PLX is 89/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

PLX reports a high gross margin of 65.7% (sector average: 40.1%) and a strong operating margin of 26.2%.

PLX shows revenue declining at 1% year-over-year, with earnings declining at 325%.

Top Value Stocks in Healthcare

Symbol	Name	Price	P/E	Score
EMBC	Embecta Corp. - Common Stock	$3.90	2.1	100
HCM	HUTCHMED (China) Limited - American Depositary Shares	$13.31	5.1	100
GMAB	Genmab A/S - American Depositary Shares	$27.06	1.8	100
CGEN	Compugen Ltd. - Ordinary Shares	$2.71	7.3	100
INVA	Innoviva, Inc. - Common Stock	$22.89	5.8	100

Browse all Healthcare value stocks →

How is the Value Score calculated?

Read our full methodology →

How is the Graham Number calculated?

Benjamin Graham's intrinsic value formula, worked examples, and how to use it →

PLUT — Plutus Financial Group Limited - Ordinary Shares

Plexus Corp. - Common Stock — PLXS